These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 10551047)

  • 21. [Telomerase activity as marker of superficial tumor of the bladder].
    Arias Fúnez F; Fernández Fernández E; Escudero Barrilero A; Moyano Jato A; Caso Peláez E
    Arch Esp Urol; 2000 Apr; 53(3):231-6. PubMed ID: 10851728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urine based markers of urological malignancy.
    Konety BR; Getzenberg RH
    J Urol; 2001 Feb; 165(2):600-11. PubMed ID: 11176445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
    J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urine: beyond cytology for detection of malignancy.
    Pattari SK; Dey P
    Diagn Cytopathol; 2002 Sep; 27(3):139-42. PubMed ID: 12203859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bladder cancer biomarkers and their role in surveillance and screening.
    Van Tilborg AA; Bangma CH; Zwarthoff EC
    Int J Urol; 2009 Jan; 16(1):23-30. PubMed ID: 19120523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
    Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB
    Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of seven screening methods in the diagnosis of bladder cancer.
    Sun Y; He DL; Ma Q; Wan XY; Zhu GD; Li L; Luo Y; He H; Yang L
    Chin Med J (Engl); 2006 Nov; 119(21):1763-71. PubMed ID: 17097029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.
    Lotan Y; Svatek RS; Sagalowsky AI
    Cancer; 2006 Sep; 107(5):982-90. PubMed ID: 16862567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of urine cytology in the assessment of lower urinary tract symptoms.
    Kouriefs C; Leris AC; Mokbel K; Carpenter R
    BJU Int; 2000 Jun; 85(9):1155. PubMed ID: 10939871
    [No Abstract]   [Full Text] [Related]  

  • 30. Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder.
    Feil G; Zumbrägel A; Päulgen-Nelde HJ; Hennenlotter J; Maurer S; Krause S; Bichler KH; Stenzl A
    Anticancer Res; 2003; 23(2A):963-7. PubMed ID: 12820331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of telomerase activity in bladder carcinoma and exfoliated cells collected in urine and bladder washings, using a quantitative assay.
    Gelmini S; Crisci A; Salvadori B; Pazzagli M; Selli C; Orlando C
    Clin Cancer Res; 2000 Jul; 6(7):2771-6. PubMed ID: 10914723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
    Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
    J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical evaluation of urinary basic fetoprotein and the BTA test for detection of bladder cancer].
    Imamura M; Inoue K; Megumi Y; Nishimura M; Ohmori K; Nishimura K
    Hinyokika Kiyo; 2000 Oct; 46(10):705-9. PubMed ID: 11215195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of urinary cytology for detection of bladder cancer.
    Planz B; Jochims E; Deix T; Caspers HP; Jakse G; Boecking A
    Eur J Surg Oncol; 2005 Apr; 31(3):304-8. PubMed ID: 15780568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The clinical efficacy of Bladder Chek NMP22 in urothelial cancer].
    Yokoyama T; Sekigawa R; Hayashi T; Horita S; Kanamuro T; Nonami Y; Sawada T; Nishikawa T; Kobayashi M; Yamaguchi Y; Ishida H; Goya N; Nakazawa H; Toma H
    Rinsho Byori; 2004 Mar; 52(3):199-203. PubMed ID: 15137316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcome of hematuria home screening for bladder cancer in men.
    Cai T; Bartoletti R
    Cancer; 2007 May; 109(9):1923-4; author reply 1924. PubMed ID: 17357998
    [No Abstract]   [Full Text] [Related]  

  • 37. [Screening methods in the detection of bladder cancer: comparison of nuclear matrix protein-22, bladder tumor antigen and cytological examinations].
    Fukui Y; Samma S; Fujimoto K; Akiyama T; Yamaguchi A; Hirayama A
    Hinyokika Kiyo; 2001 May; 47(5):311-4. PubMed ID: 11433750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis.
    Tritschler S; Scharf S; Karl A; Tilki D; Knuechel R; Hartmann A; Stief CG; Zaak D
    Eur Urol; 2007 Feb; 51(2):403-7; discussion 407-8. PubMed ID: 16939699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening and monitoring for bladder cancer: refining the use of NMP22.
    Ponsky LE; Sharma S; Pandrangi L; Kedia S; Nelson D; Agarwal A; Zippe CD
    J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [ImmunoCyt--a new urine test in diagnosis of bladder cancer].
    Feil G; Bichler KH; Päulgen-Nelde HJ; Hennenlotter J; Zumbrägel A; Stenzl A
    Urologe A; 2003 Apr; 42(4):531-7. PubMed ID: 12715125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.